FDA Deputy Commissioner for Technology and AI — Jared Seehafer Appointment
ENTITYOverview HHS selected Jared Seehafer as the FDA's first-ever Deputy Commissioner for Technology and Artificial Intelligence, announced in a September 8 HHS news release. This appointment establishes a dedicated senior leadership role at the FDA focused exclusively on technology and AI oversight — a structural first for the agency. Context The appointment came alongside the selection of three other senior FDA leaders, including directors for the agency's drug, biologics, and tobacco centers. The creation of a dedicated AI deputy commissioner role signals the FDA's recognition that AI-enabled medical device regulation has grown sufficiently complex to require dedicated executive leadership. Significance Seehafer's appointment is notable given the volume of FDA activity around AI medical devices in 2026, including the TEMPO pilot for generative AI devices, the adaptive AI devices public input process, and ongoing debates about the clinical outcomes evidence gap for cleared AI devices. A dedicated deputy commissioner role is expected to accelerate policy development and regulatory coherence across the agency's AI-related activities. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.